Kezar Life Sciences

Developing novel therapeutics to treat unmet needs in autoimmunity and cancer

Kezar Life Sciences is focused on discovering and developing novel small molecule therapeutics to address unmet needs in autoimmunity and cancer. The company’s lead product candidate (KZR-616) is a potential first-in-class selective immunoproteasome inhibitor, and is currently in a Phase 1b/2 clinical trial for lupus and lupus nephritis.

Status

IPO in 2018 (NASDAQ: KZR)

Year of Investment

2018

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

South San Francisco, California